Apellis Pharmaceuticals (NASDAQ:APLS) Insider Pascal Deschatelets Sells 2,277 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Pascal Deschatelets sold 2,277 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total transaction of $50,526.63. Following the transaction, the insider owned 1,158,219 shares in the company, valued at $25,700,879.61. The trade was a 0.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Apellis Pharmaceuticals Price Performance

APLS stock traded up $0.20 during mid-day trading on Thursday, reaching $20.53. The company’s stock had a trading volume of 2,191,474 shares, compared to its average volume of 3,495,767. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The company’s 50 day moving average is $22.86 and its two-hundred day moving average is $23.41. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $31.17. The stock has a market cap of $2.60 billion, a PE ratio of 66.23 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. During the same period in the prior year, the business earned ($0.46) earnings per share. The business’s revenue was up 133.0% compared to the same quarter last year. Equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Deep Track Capital LP increased its position in shares of Apellis Pharmaceuticals by 14.3% during the third quarter. Deep Track Capital LP now owns 8,000,382 shares of the company’s stock valued at $181,049,000 after acquiring an additional 1,000,382 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Apellis Pharmaceuticals by 46.6% during the 2nd quarter. AQR Capital Management LLC now owns 5,976,414 shares of the company’s stock worth $103,452,000 after purchasing an additional 1,898,995 shares during the period. Marshall Wace LLP increased its holdings in Apellis Pharmaceuticals by 11,373.8% in the 2nd quarter. Marshall Wace LLP now owns 2,704,837 shares of the company’s stock valued at $46,821,000 after purchasing an additional 2,681,263 shares during the last quarter. Jennison Associates LLC increased its holdings in Apellis Pharmaceuticals by 7.4% in the 2nd quarter. Jennison Associates LLC now owns 2,661,823 shares of the company’s stock valued at $46,076,000 after purchasing an additional 184,292 shares during the last quarter. Finally, Polar Capital Holdings Plc raised its position in Apellis Pharmaceuticals by 96.0% in the third quarter. Polar Capital Holdings Plc now owns 2,650,230 shares of the company’s stock valued at $59,975,000 after purchasing an additional 1,298,055 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on APLS. Wolfe Research initiated coverage on Apellis Pharmaceuticals in a report on Thursday, November 6th. They set a “peer perform” rating on the stock. Wells Fargo & Company started coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They set an “overweight” rating and a $32.00 target price on the stock. TD Cowen decreased their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Citigroup cut their price target on shares of Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. Finally, William Blair reaffirmed an “outperform” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 15th. Eleven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $33.65.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.